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Introduction
Uterine myomas (called “myomas”) are the most com-
mon benign tumors in the female reproductive tract,
with an incidence ranging from 5.4% to 77% [1,2], and
without the threat of mortality and with little influence
on morbidity [3]. The precise etiology of myomas has
not been well elucidated, but it is assumed to be
closely related to hormonal exposures, the promotion
of growth factors or genetic changes [4]. Based on
clinical observation and epidemiologic data, myomas
develop and grow during the reproductive years and
regress after menopause, indicating the critical role of
estrogen in the pathogenesis of myomas. The use of
estrogen agonists or postmenopausal hormone therapy
appears to increase the incidence of myomas [5], sug-
gesting that sex hormones may play key factors in the
pathogenesis of myomas.
The following findings support the important role
of sex hormones in the development of myoma: (1)
rare occurrence before puberty but most prevalent
during the reproductive years, and regressing after
menopause; (2) increased incidence by factors such as
obesity and early menarche that increase overall life-
time exposure to estrogen; and (3) difference in sex
hormone receptor concentrations between the normal
myometrium and uterine myoma [6,7]. Besides the
role of estrogen in the pathogenesis of uterine myomas,
progesterone may be also a key factor. The inconsis-
tencies in the clinical effects of progesterone on
myomas may be explained by dual actions on the
growth of uterine myomas in several in vivo studies.
Progesterone stimulates the proliferation of myoma
cells by inducing the epidermal growth factor [8],
upregulating antiapoptotic protein Bcl-2 expression
[9], and decreasing tumor necrosis factor-α expres-
sion [10]. On the other hand, progesterone inhibits
myoma growth via downregulation of insulin-like
growth factor-I expression [11]. Since sex hormones
and sex hormone receptors are involved in the patho-
genesis of myomas, the underlying mechanism of
almost all medical therapy is based on the blockage of
the receptor mechanism in myomas. Currently available
and well-accepted medical treatments for myomas
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should be classified as non-hormonal treatment or
hormonal treatment.
Medical Treatment
Most women with myomas are asymptomatic. Therefore,
expectant observation and follow-up are often recom-
mended for these myoma patients. However, myomas
may cause menstrual symptoms, pelvic pain, pressure
complaints, subfertility or pregnancy-related compli-
cations, and a rare threatening condition, with resul-
tant requests for a definitive treatment [12–18].
The management of myomas has become multidis-
ciplinary in the past 20 years. Basically, the choice of
treatment depends on the patient’s age, the reason for
treatment, the issue of fertility preservation, and the
patient’s preference. The treatment spectrum includes
an expectant management, medical therapy, surgical
intervention, uterine artery embolization or ablative
techniques [19–22]. Medical therapy is an option for
women with symptomatic myomas who prefer non-
surgical treatment, consider fertility preservation, or
expect a less aggressive operation after shrinkage of
the uterine volume.
Non-steroidal Anti-inflammatory Drugs
Non-steroidal anti-inflammatory drugs are a main
part of non-hormonal therapy for myomas, although
their efficacy has not been proved [19]. The main hor-
mone therapy is gonadotropin-releasing hormone
(GnRH) agonists or antagonists [19].
GnRH Agonist
GnRH agonist may be the most effective drug in the
management of myomas. It is an analogue of endo-
genus GnRH and binds to pituitary GnRH receptors
(GnRH-R), leading to synthesis and release of the
luteinizing hormone and follicular stimulating hormone.
Compared with GnRH, GnRH agonist has a longer half-
life that causes a continuous exposure of GnRH-R
under the activity of GnRH agonists. Downregulation of
GnRH-R consequently results in a decreased level 
of gonadotropin and suppressed production of the
ovarian hormone [23–25]. GnRH agonists produce 
a transient menopausal condition.
The effects of GnRH agonists include decrements
in the volume of myoma nodules and the uterus [25].
The decrease in myoma volume is variable, ranging from
27% to 70% [26–28]. Although GnRH agonist con-
tributes to the shrinkage of myoma volume by induc-
ing a transient menopausal status thereby resulting in
low estrogen and low progesterone subsequently, the
underlying mechanism of GnRH agonists in shrinking
myomas is still controversial [29–31]. Many associated
factors have been reported, including cellular atrophy,
a decrease in cell proliferation, and reduced trophic
mediators or uterine blood flow. Cellular atrophy of
individual myoma cells may be due to a decrease in
myofilaments within the myoma cells [32]. Changes in
the number of myoma cells could be explained by
increased cell necrosis and apoptosis [33–35], enhanced
deoxyribonucleic acid damage and repair [36] or, pos-
sibly, vasoconstriction [37]. Since GnRH agonist can
result in the menopausal status, menorrhagia can be
alleviated [38] and myoma-related anemia be success-
fully treated by GnRH agonists [37].
There are various forms of GnRH agonists that may
be administered intramuscularly, subcutaneously or by
intranasal absorption [39]. These include leuprolide,
buserelin, nafarelin, histrelin, goserelin, deslorelin, and
triptorelin. The therapeutic effect is achieved by 
a reduction of median estradiol levels within an 80 to
180 pmol/L window [25]. In relation to alleviating
menorrhagia, bleeding problems or related anemia are
controlled in women after the first month of treat-
ment. By reducing the uterine and myoma size, pain and
pressure symptoms are relieved in the first 2 months.
Maximal diminution of uterine and myoma size is
achieved within the first 12 weeks of therapy [40].
However, the effect of GnRH agonists on the reduc-
tion of myoma size is transient. The reversal of estro-
gen deprivation takes about 4 weeks after discontinuation
of GnRH agonist [41]. Most myoma nodules return to
their initial size within about 6 months after discontin-
uation of GnRH agonist treatment. The rate of enlarge-
ment is rapid compared with natural enlargement
[42], and regrowth of the uterus and myomas leads to
a return of initial symptoms.
The significant disadvantages of GnRH agonists
are hypoestrogenism-related untoward effects, resem-
bling postmenopausal climacteric disturbances and
bone loss [43,44]. Partial restoration of the estrogenic
state by reduced-dose therapy or steroid “add-back” is
proven to be effective for the relief of annoying side
effects without the loss of the beneficial effects on
myoma size and cycle suppression [45]. Addition of
oral veralipride, a benzamide derivative, can reduce
the vasomotor symptoms induced by a GnRH agonist
[46]. Raloxifene or tibolone may also be the ideal add-
back therapy to prevent bone loss but preserve the effi-
cacy of GnRH agonists [47,48]. However, raloxifene
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administration did not reduce vasomotor symptoms
related to GnRH agonists [47]. In contrast, a signifi-
cant reduction of hot flushes was observed when
adding tibolone to GnRH agonist treatment [48,49].
Since GnRH agonists are expensive, several surveys
have tried to investigate clinical parameters to predict
the response to GnRH agonists. GnRH agonists have
remarkable therapeutic efficacy in myomas, with the
characteristics of a high concentration of unbound
progesterone receptors [50], positive blood flow by
Doppler ultrasound [51] but not in myomas with 
a hypoechoic appearance [52], high hyaline change or
collagenous tissues [53], chromosomal rearrangement
[54], or a pedunculated or cervical type [55]. In the
management of myomas, GnRH agonists are currently
assumed as an adjuvant therapy for preoperative
preparation. The reduction of the myoma or uterine
volume provides an advantage in simplifying the surgi-
cal procedure and decreasing operative morbidity
(such as blood loss and operating time).
GnRH Antagonist
GnRH antagonists were concomitantly developed 
with GnRH agonists. However, the clinical application
of GnRH antagonists is restricted by patient hypersen-
sitivity. In contrast with the desensitization of GnRH-R
by GnRH agonists, GnRH antagonists directly com-
pete with endogenous GnRH for pituitary binding
sites. GnRH antagonists suppress gonadotropin release
within 4 to 8 hours in the absence of an initial “flare-
up” effect. Theoretically, GnRH antagonists can achieve
treatment effects similar to GnRH agonists within a
shorter time span. However, the activity of GnRH
antagonists is dose-dependent, and inhibitory effects
should be attained by dose modification. Currently,
GnRH antagonists are market-licensed for the indica-
tion of premature luteinizing hormone surge preven-
tion in controlled ovarian hyperstimulation and the
palliative treatment of advanced prostate cancer. The
three commercially available GnRH antagonists are
cetrorelix (Cetrotide; Serono International SA, Geneva,
Switzerland), ganirelix (Orgalutran/Antagon; Organon,
Oss, The Netherlands), and abarelix (Plenaxis; Praecis
Pharmaceuticals Inc., Waltham, MA, USA).
Results of available clinical trials employing GnRH
antagonists for the treatment of uterine myomas are
indeterminate owing to uncontrolled settings, differ-
ences in regimen characteristics, and varied adminis-
tration routes and dose sizes. Overall, ovarian suppression
is observed within 48 hours, and a nadir of estradiol
level is reached on day 7 of treatment [56,57]. Although
shrinkage of uterine myomas by 25% to 50% may be
observed after 2 to 8 weeks, a lack of response was fre-
quently reported [58,59]. Variance in size reduction
between individual patients makes the response to
GnRH antagonists less reliable than predicted by the
established usage of GnRH agonists.
Recently, cetrorelix acetate (Cetrotide; ASTA Medica
AG, Halle, Germany), a more effective, longer acting,
safer third-generation GnRH antagonist, showed in-
creased apoptosis of leiomyoma cells in an in vitro study.
The induced apoptosis may be associated with a defi-
ciency of sex hormones as well as upregulation of pro-
apoptotic factors expression [60]. The effect of GnRH
agonists is temporary, as uterine myomas achieve their
original size soon after treatment discontinuation.
Therefore, the role of GnRH antagonists in the treatment
of uterine myomas should be reserved as a feasible
preoperative regimen.
Progesterone-mediated Intrauterine System
Levonorgestrel-releasing intrauterine system (LNg-IUS)
is a T-shaped intrauterine device sheathed with a reser-
voir of 52 mg of 19-norprogestin levonorgestrel released
at the daily rate of 20 µg [61]. Through its slow delivery
of progesterone, LNg-IUS has been proven to reduce the
duration of bleeding and the amount of menstrual loss
owing to the inhibition of endometrial proliferation, as
well as enhancement of cellular apoptosis [62]. It may
be a therapeutic modality for myoma-associated men-
orrhagia and anemia [63,64]. The effect on reduction
of myoma-related menorrhagia is weakened by an
enlarged uterine cavity, severe blood loss prior to treat-
ment, or irregular intermenstrual bleeding [65]. In terms
of the reduction of uterine and myoma volume, an
inconsistent effect was found during LNg-IUS use, and
no significant differences were found in myoma volume
after a 12-month usage of LNg-IUS [63].
Limitation of Medical Treatment
Without doubt, malignant uterine tumor should be an
absolute contraindication of medical therapy [66].
Before we treat uterine myomas without evidence of
pathology, the most important issue is to determine
whether the uterine sarcomas arise from malignant
transformation of pre-existing myomas [67,68]. If 
a physician is unable to answer this question with 
certainty, medical treatment for uterine myomas
might carry a risk. For this reason, the pathogenesis of
leiomyosarcoma and leiomyoma should be affirmed.
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Conclusion
If no symptoms of uterine myomas exist, no therapy is
required. Regular follow-up may be the first choice for
women with uterine myomas. However, if symptoms
or signs exist, treatment should be initiated without
hesitancy. Most current medical therapy for uterine
myomas is based on the hypothesis that uterine myoma
is an ovarian steroid-dependent disease. Therefore,
estrogen deprivation or progesterone-mediated ther-
apy is always the choice if conservative or medical
treatment is requested. Since estrogen deprivation in
these relatively young women results in many unwanted
side effects, combinations of several treatments for
myomas may be a potential therapeutic modality in
the future. The idea originated from an incidental
finding of “add-back” therapy. Adjuvant therapy for
relief of untoward effects is found to have additive
benefit. Finally, with the advanced techniques of molec-
ular biology, discovery of other myoma-related growth
factors or the exploration of growth factor inhibitors
in myomas will be an alternative in treating myomas.
Besides medical treatment, other modalities, such as
uterine artery embolization, ablative techniques and
focused ultrasound surgery, may be alternative conser-
vation treatment. Of course, definitive surgical treat-
ment should not be neglected as a rescue method in
the management of uterine myomas.
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